Trial Profile

Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blinatumomab (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Idarubicin; Mercaptopurine; Methotrexate; Pegaspargase; Vincristine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Acronyms BOLD; EWALL-BOLD

04 May 2024 Status changed from recruiting to completed.
12 Dec 2023 Results assessing dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph/BCR ABL Negative B-Precursor Adult Lymphoblastic Leukemia, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
16 Aug 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com